| Literature DB >> 32335545 |
Andy Chun Hang Chen1,2, Qian Peng2, Sze Wan Fong1, William Shu Biu Yeung1,2, Yin Lau Lee1,2.
Abstract
Sirt1 facilitates the reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs). It is regulated by micro-RNA and reported to be a target of miR-135a. However, their relationship and roles on cellular reprogramming remain unknown. In this study, we found negative correlations between miR-135a and Sirt1 during mouse embryonic stem cells differentiation and mouse embryonic fibroblasts reprogramming. We further found that the reprogramming efficiency was reduced by the overexpression of miR-135a precursor but induced by the miR-135a inhibitor. Co-immunoprecipitation followed by mass spectrometry identified 21 SIRT1 interacting proteins including KU70 and WRN, which were highly enriched for DNA damage repair. In accordance, Sirt1 activator resveratrol reduced DNA damage during the reprogramming process. Wrn was regulated by miR-135a and resveratrol partly rescued the impaired reprogramming efficiency induced by Wrn knockdown. This study showed Sirt1, being partly regulated by miR-135a, bound proteins involved in DNA damage repair and enhanced the iPSCs production.Entities:
Keywords: DNA damage repair; Sirt1; cellular reprogramming; miR-135a; mouse induced pluripotent stem cells
Year: 2020 PMID: 32335545 PMCID: PMC7202538 DOI: 10.18632/aging.103090
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1miR-135a impeded reprogramming efficiency partly through inhibiting (A) The effects of miR-135a precursor or inhibitor on relative number of iPSC colonies formed from 1° (n=4) or 2° (n=7) MEFs on D10/15 after Doxycycline (DOX) induction. miRNA precursor (pre-ctrl) and inhibitor (inh-ctrl) with scrambled sequence were used as controls (*:p<0.05; t-test). (B) The relative expression levels of miR-135a in MEFs and mESCs (n=3; *: p<0.05; t-test). (C) The relative expression levels of miR-135a in 1° MEFs after transfecting with miR-135a precursor (pre-135a) or inhibitor (inh-135a) for 72h (n=4; *:p<0.05; t-test). (D) The relative SIRT1 and SIRT6 protein levels in 1° MEFs after transfecting with miR-135a precursor (pre-135a) or inhibitor (inh-135a) for 72h (n=4; *:p<0.05; t-test). (E) The relative expression levels of miR-135a in mESCs and EBs at day 17 (EB-D17, n=3; #:p<0.001; t-test). (F) The relative miR-135a expression levels during reprogramming of 2° MEFs from day 0 to day 21 (n=3; *:p<0.05; t-test). (G) The relative expression levels of miR-135a in 1° MEFs after RSV treatment for 72h (n=4; t-test).
Figure 2Identification of the SIRT1 interacting proteins during initiation phase of reprogramming. (A) 2° MEFs containing DOX inducible MKOS was sorted out by FACS according to the FITC gating indicated by circle dash line. (B) co-immunoprecipitation assay using SIRT1 antibody or rabbit IgG followed by Western blotting analysis (IB) using antibodies against SIRT1, KU70 and WRN.
Sirt1 interacting proteins during the initiation phase of miPSCs production identified by LC-ESI-Ion Trap mass spectrometry.
| myosin-XVIIIa | gi|22094119 | 231791 | 1670 |
| Kif21a | gi|6561827 | 176938 | 327 |
| WRN protein | gi|7595900 | 159196 | 197 |
| enhancer of mRNA-decapping protein 4 | gi|31712002 | 151928 | 117 |
| glutamyl-prolyl-tRNA synthetase | gi|148681120 | 166980 | 115 |
| FH1/FH2 domain-containing protein 1 | gi|269973931 | 130774 | 1784 |
| DNA repair protein RAD50 | gi|60392985 | 154533 | 1056 |
| valyl-tRNA synthetase | gi|4590328 | 141523 | 1019 |
| gamma-tubulin complex component 3 | gi|39930567 | 104145 | 1057 |
| gamma-tubulin complex component 2 | gi|21362572 | 103796 | 608 |
| heterogenous nuclear ribonucleoprotein U | gi|3329496 | 88635 | 151 |
| gamma-tubulin complex component 5 | gi|46560557 | 118815 | 135 |
| dynamin-like 120 kDa protein, mitochondrial isoform 2 precursor | gi|19526960 | 111783 | 1009 |
| double-strand break repair protein MRE11A | gi|9055282 | 80572 | 506 |
| nedd-1 protein | gi|286103 | 71891 | 857 |
| Stress-70 protein, mitochondrial | gi|14917005 | 73768 | 814 |
| heat shock protein 70 cognate | gi|309319 | 71021 | 505 |
| gamma-tubulin complex component 4 | gi|23943924 | 76592 | 272 |
| ATP-dependent RNA helicase DDX3X | gi|6753620 | 73455 | 117 |
| X-ray repair cross-complementing protein 6 | gi|145587104 | 69727 | 93 |
| Elongation factor 1-delta | gi|13124192 | 31388 | 2929 |
Gene ontology and KEGG pathway analysis of the enriched Sirt1 interacting proteins during the initiation phase of miPSCs production.
| GO:0051415~interphase microtubule nucleation by interphase microtubule organizing center | Tubgcp4, Tubgcp5, Tubgcp3, Tubgcp2 | 574.0317 | 2.31E-08 |
| GO:0007020~microtubule nucleation | Tubgcp4, Tubgcp5, Tubgcp3, Tubgcp2 | 215.2619 | 6.42E-07 |
| GO:0032508~DNA duplex unwinding | Xrcc6, Rad50, Wrn, Mre11a | 191.3439 | 9.34E-07 |
| GO:0051298~centrosome duplication | Tubgcp4, Tubgcp5, Tubgcp3, Tubgcp2 | 156.5541 | 1.76E-06 |
| GO:0007126~meiotic nuclear division | Tubgcp4, Tubgcp5, Tubgcp3, Tubgcp2 | 143.5079 | 2.31E-06 |
| GO:0090307~mitotic spindle assembly | Tubgcp4, Tubgcp5, Tubgcp3, Tubgcp2 | 98.40544 | 7.40E-06 |
| GO:0031122~cytoplasmic microtubule organization | Tubgcp4, Tubgcp5, Tubgcp3, Tubgcp2 | 95.67196 | 8.07E-06 |
| GO:0006302~double-strand break repair | Xrcc6, Rad50, Wrn, Mre11a | 54.66969 | 4.40E-05 |
| GO:0000226~microtubule cytoskeleton organization | Tubgcp4, Tubgcp5, Tubgcp3, Tubgcp2 | 35.87698 | 1.55E-04 |
| GO:0000723~telomere maintenance | Xrcc6, Rad50, Wrn | 67.97744 | 7.98E-04 |
| GO:0006974~cellular response to DNA damage stimulus | Xrcc6, Sirt1, Rad50, Wrn, Mre11a | 10.25057 | 0.001035 |
| GO:0006310~DNA recombination | Xrcc6, Rad50, Wrn | 30.38992 | 0.003927 |
| GO:0031860~telomeric 3' overhang formation | Rad50, Mre11a | 430.5238 | 0.004417 |
| GO:0006281~DNA repair | Xrcc6, Rad50, Wrn, Mre11a | 10.83079 | 0.00492 |
| GO:0000731~DNA synthesis involved in DNA repair | Sirt1, Wrn | 215.2619 | 0.008816 |
| GO:0032206~positive regulation of telomere maintenance | Rad50, Mre11a | 172.2095 | 0.011009 |
| GO:0000722~telomere maintenance via recombination | Rad50, Wrn | 156.5541 | 0.012103 |
| GO:0033674~positive regulation of kinase activity | Rad50, Mre11a | 143.5079 | 0.013196 |
| GO:0031954~positive regulation of protein autophosphorylation | Rad50, Mre11a | 95.67196 | 0.019732 |
| GO:0046597~negative regulation of viral entry into host cell | Rad50, Mre11a | 86.10476 | 0.021902 |
| GO:0006303~double-strand break repair via nonhomologous end joining | Xrcc6, Mre11a | 82.00454 | 0.022985 |
| GO:0043066~negative regulation of apoptotic process | Sirt1, Mre11a, Ddx3x, Myo18a | 6.085142 | 0.023396 |
| GO:0071480~cellular response to gamma radiation | Xrcc6, Wrn | 71.75397 | 0.026227 |
| GO:0010667~negative regulation of cardiac muscle cell apoptotic process | Sirt1, Hspa8 | 66.23443 | 0.028383 |
| GO:2001243~negative regulation of intrinsic apoptotic signaling pathway | Ddx3x, Opa1 | 63.78131 | 0.029459 |
| GO:0071479~cellular response to ionizing radiation | Eef1d, Sirt1 | 55.55146 | 0.033753 |
| GO:0006418~tRNA aminoacylation for protein translation | Eprs, Vars | 47.83598 | 0.039095 |
| GO:0007346~regulation of mitotic cell cycle | Sirt1, Rad50 | 46.54311 | 0.04016 |
| GO:0051276~chromosome organization | Rad50, Mre11a | 45.3183 | 0.041223 |
| mmu03450: Non-homologous end-joining | Mre11a, Rad50, Xrcc6 | 148.4615 | 1.43E-04 |
| mmu03440: Homologous recombination | Mre11a, Rad50 | 45.95238 | 0.039206 |
Figure 3The effects of RSV on DNA damage markers during reprogramming. Immunocytochemistry analysis on expression of (A) γH2AX and (B) 53BP1 in 2° MEFs before (-DOX) and after (+DOX) treatment. (C) FACS analysis showing the effect of RSV on γH2AX expression. (D) The numbers of cells with more than five (>5 foci, white), three to five (3-5 foci, black), one to two (1-2 foci, grey) and no (no foci, stripped) 53bp1 foci without (+DOX) or with (+RSV) RSV treatment. (n=3; *: p<0.05 when compared to the same category; chi square test).
Figure 4The effects of KU70 and WRN on reprogramming efficiencies. (A) The relative protein expressions of KU70, WRN and SIRT1 in reprogramming MEFs on D5 and D10 upon DOX treatment. (n=3; *: p<0.05 when compared with MEFs; one way ANOVA). (B) The relative protein expression levels of KU70 and WRN in 2°F MEFs without (Ctrl) or with (RSV) RSV treatment after DOX induction. (C) The relative number of colonies formed after transfection with Ku70 (si-Ku70) or Wrn (si-Wrn) siRNA with or without the addition of RSV during the reprogramming. (n=3; *: p<0.05 as compared to siRNA control (si-ctrl); #: p<0.05 when compared with or without the addition of RSV; one way ANOVA). (D) The relative protein expressions of WRN in 1° MEFs after transfecting with miR-135a precursor (pre-135a) or inhibitor (inh-135a) for 72h (n=4; *:p<0.05; t-test). (E) The relative number of colonies formed after co-transfection with miR-135a inhibitor (inh-135a) and Sirt1 siRNA (si-Sirt1) during the reprogramming. (n=6; *: p<0.05 as compared to co-transfection with miRNA inhibitor control (inh-ctrl) and siRNA control (si-ctrl); one way ANOVA).